Aids researchers seek go-ahead to test thalidomide: Drug trial planned on HIV-positive men
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Monday 26 July 1993
Doctors at St George's Hospital Medical School and the Chelsea and Westminster Hospital in London have applied for ethical approval to begin the drugs trial which they expect to start at the end of next month.
Professor Angus Dalgleish, an Aids researcher at St George's, said he had been applying to start a trial of thalidomide as an anti-Aids drug for 'the best part of a year'.
He said 40 patients had volunteered, the drug had been bought from a company in Brazil and the EC had agreed to fund the study. 'We're just waiting for final ethical approval,' he said.
'We're hoping to start as soon as possible, possibly the end of August. I think it should be OK because we've had our submission before (the ethical panel) several times now.'
Thalidomide, which was initially sold as a sedative and is now used to treat leprosy, is believed to 'damp down' a part of the immune system that Professor Dalgleish believes is responsible for helping to bring on Aids in people infected with HIV.
Researchers at the Rockefeller University in New York reported earlier this year that they believed thalidomide could alleviate the symptoms of Aids and slow or even halt its progress.
Professor Dalgleish believes that HIV causes the body's immune system to attack its own cells, similar to other so-called 'auto-immune' diseases. However, many other scientists disagree, which has frustrated Professor Dalgleish's attempts to begin a trial of thalidomide in the UK, he said.
Another problem has been the terrible notoriety of the drug itself. 'No drug company wants to have its name associated with it. We've had to buy it from a company in Brazil that is making it for leprosy treatment.'
He said the ethical protocol of the drugs trial made it 'absolutely mandatory' for all 40 volunteers to be men because of the risk of birth defects in women.
- 1 School playground evacuated over 'unusually aggressive' grey squirrel
- 2 Hollywood actor Mickey Rourke beats opponent 33 years his junior in exhibition boxing match
- 3 Jennifer Lawrence scores first UK top 40 single with Hunger Games track 'The Hanging Tree'
- 4 Today was a bad day for renters, landlords, and democracy
- 5 'You should come to my house and eat cheeses with me': 4-year-old sends adorable love letter to girl at school
At least 100 dead after Islamists launch attack on Nigerian mosque
Hollywood actor Mickey Rourke beats opponent 33 years his junior in exhibition boxing match
'You should come to my house and eat cheeses with me': 4-year-old sends adorable love letter to girl at school
Scientists predict green energy revolution after incredible new graphene discoveries
Russell Brand: 'Katy Perry? I don’t know who that is'
Obama: The only people with the right to object to immigration are Native Americans
Ukip says babies born to immigrants in the UK should be classed as migrants – which would include Nigel Farage’s own children
The young are the new poor: Sharp increase in number of under-25s living in poverty, while over-65s are better off than ever
David Cameron sets out immigration reforms: We should distrust Ukip and their 'snake-oil of simple solutions'
Ukip mocked after mistaking Westminster Cathedral – for a mosque
Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
£30k - 38k per year + Benefits: Opilio Recruitment: An award-winning consume...
£40k - 45k per year + Benefits: Opilio Recruitment: A fantastic opportunity ...
£30k - 35k per year + Benefits: Opilio Recruitment: We’re currently re...
£35k - 45k per year + benefits: Opilio Recruitment: A fantastic opportunity ...